GlassScriptPhysician profile
Marissa Howard
NPI 1750819967
$1,940.51
in general payments reported to CMS, 2019-2025
27 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $571 · 2023: $650 · 2024: $106 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $358.81 | 2021-2025 | Farxiga, Lokelma, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.58 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $160.07 | 2021-2025 | |
| Amgen INC. | $140.45 | 2021-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $127.07 | 2021-2023 | |
| Mylan Specialty L.P. | $115.33 | 2023-2024 | Yupelri |
| Pfizer INC. | $77.79 | 2021-2023 | |
| Travere Therapeutics, INC. | $75.41 | 2023 | |
| Janssen Pharmaceuticals, INC | $73.71 | 2022 | |
| Novo Nordisk INC | $65.54 | 2021-2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $62.85 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $47.42 | 2021 | |
| Lilly USA, LLC | $41.87 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.86 | 2022-2023 | Jynarque |
| Biohaven Pharmaceutical Holding Company LTD. | $36.47 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $29.30 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.22 | 2022 | |
| Axsome Therapeutics, INC. | $21.13 | 2025 | Auvelity |
| Viatris Specialty LLC | $20.05 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $19.99 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.72 | 2023 | |
| Apellis Pharmaceuticals, INC. | $17.82 | 2025 | Empaveli |
| Astellas Pharma US INC | $16.35 | 2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $13.78 | 2023 | Arexvy |
| Nxstage Medical, INC. | $13.49 | 2023 | Nxstage System One |
| Novartis Pharmaceuticals Corporation | $13.41 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.02 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.